Viktor Dmitriev: ARPM considers the time frame for the pilot project on labeling medicines is feasible

On September 13th the official website of the Kommersant newspaper published an article "Medicines do not keep the brand", deforming the words of the General Director of the ARPM Viktor Dmitriev.


Citation from the article:


"Members of the Association of the Russian Pharmaceutical Manufacturers (ARPM), including Stada, AstraZeneca, Bayer, suggest adjourning the turnover period to total marking of medicines from 2019 to 2021. They are afraid that 80% of manufacturers need more time to install the necessary equipment by the appointed time and unmarked medicines will be illegal at the market. "


Regarding this, the ARPM announces that the article contains deformed information: the Association of the Russian Pharmaceutical Manufacturers, as well as the pharmaceutical companies — members of the ARPM, do not propose to adjourn the turnover date of total marking and did not do any surveys on this matter. Also, Bayer is not a member of the ARPM.


"Marking of medicines is the project that was signed and approved by the Presidium of the Council under the President of the Russian Federation. The project participants see the positive results, and consider marking as a tool that allows tracking the movement of the medicine from the producer to the users and preventing the admission of falsified products to the market. This project is definitely important for the modern market, — Viktor Dmitriev believes. — Currently, within the framework of the working group in Roszdravnadzor, a planned work is in process to implement the pilot project, which I am sure will be qualitative and implemented on time, for the benefit of the Russian patients and medicine manufacturers. "

Пресс-служба АРФП